Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer.

JCO precision oncology - 1 Nov 2022

Cheng Michael L, Lee Jessica K, Kumar Rachit, Klein Harry, Raskina Kira, Schrock Alexa B, Michael Kesi S, Mazor Tali, Cerami Ethan, Oxnard Geoffrey R, Liu David, Beltran Himisha, Sholl Lynette M, Nishino Mizuki, Jänne Pasi A

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Genomics
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to MAP Kinase Kinase 1

Share to Melanoma and MAPK Pathways

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 36455195
DOI: 10.1200/PO.22.00382

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer.PMID 36455195Read ↗

MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.Semantic proximity Read ↗

Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.Semantic proximity Read ↗

Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications.Semantic proximity Read ↗

Targeting MEK in non-small cell lung cancer.Semantic proximity Read ↗

Integrative Pan-cancer Analysis of MEK1 Aberrations and the Potential Clinical ImplicationsSemantic proximity Read ↗

Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancersSemantic proximity Read ↗

Deciphering the Complexity of MEK Mutations in the Clinic.Semantic proximity Read ↗

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.Semantic proximity Read ↗

Lung cancer profiling: Genetic and molecular predictors of MEK-dependence.Semantic proximity Read ↗

Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.Semantic proximity Read ↗

Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers.Semantic proximity Read ↗

Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.